# Tenalisib

Source: https://onco.cc/drugs/tenalisib/  
OnCo record `tenalisib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer.

## Summary

Tenalisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Rhizen Pharmaceuticals SA, in triple-negative breast cancer. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: RP6530
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral PI3K inhibitor
- Mechanism: A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.

## Sources

- ClinicalTrials.gov: trials of Tenalisib: https://clinicaltrials.gov/search?intr=Tenalisib

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- trials: [Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)](https://onco.cc/trials/nct06189209/)

---
JSON: https://onco.cc/api/v1/entities/tenalisib.json